Aims To quantify the risk of serious blood and skin disorders requiring hospitalization among otherwise healthy users of co-trimoxazole Methods We conducted a population-based cohort study at Group Health Cooperative of Puget Sound (GHC). Results During the years 1987 to 1993 we found six cases of co-trimoxazoleassociated blood disorders and three cases of co-trimoxazole-associated skin disorders yielding risks of 5.6/100,000 (95% CI 2.6-12.2) and 2.8/100,000 (95% CI 0.9-8.2) respectively. In all cases found there was prompt recovery after discontinuation of co-trimoxazole. We found no cases of toxic epidermal necrolysis. Conclusions We conclude that the risk of blood and skin disorders associated with the use of co-trimoxazole leading to hospitalization is low.
Hospital discharge summaries together with available Introduction consultation reports were obtained for all patients to identify a potentially drug-inducible illness. Case histories were Serious blood and skin disorders associated with co-trimoxazole have been described in numerous reports reviewed by the authors who gave strong consideration to the clinical diagnoses made by the physicians who cared for [1-4]. We have previously published the results of a population-based cohort study providing quantitative inforthe patients. mation on the risk of co-trimoxazole-associated serious blood and skin disorders using data from the General Practice Results Research Database (GPRD) in the United Kingdom [5] . In order to provide further quantification of this risk, we
We identified 107,689 eligible subjects who filled 229,386 performed a similar study based on information obtained prescriptions for co-trimoxazole. Thirty-one percent were from Group Health Cooperative of Puget Sound.
below age 20 years, 45% were age 20-59, and 24% were age 60 years or older. Sixty-five percent were women and Methods 57% received only one prescription for the drug. We identified and reviewed the clinical records of 24 Group Health Cooperative (GHC) is a consumer-owned patients with a coded hospital discharge diagnosis of a blood organization that provides medical care at clinics and or skin disorder. After review fifteen patients were excluded: hospitals in the Seattle, Washington area [6] . As of 1994 it four diagnosed with idiopathic thrombocytopenic purpura, had more than 380 000 members. The plan covers the cost three with a viral illness, one each with AIDS (not of ambulatory and inpatient medical care and most prescripdocumented on the computer record), infection, plasmations. Automated files of drugs dispensed to individual cytosis, collagen vascular disease, and undocumented study members have been maintained since July 1975. Information drug exposure; two had the illness prior to receipt of on admissions to Group Health hospitals, including discharge co-trimoxazole, and in one the diagnosis was not confirmed. diagnoses, have been recorded on computer since 1972 [6] .
There remained nine patients with an illness for which a For the current study we identified all persons in the causal connection with co-trimoxazole could not be ruled Seattle area, who filled at least one prescription for out. Six had a newly-diagnosed blood disorder and three co-trimoxazole between January 1, 1987 and December 31, patients had a newly-diagnosed skin disorder, (see Table 1 1993 and identified those hospitalized with a diagnosis of a for details). potentially serious blood disorder [7] Blood disorders co-trimoxazole. Patients with a diagnosis of cancer or acquired immunodeficiency syndrome (AIDS) prior to the Among the six patients with blood disorders, a causal connection to co-trimoxazole was considered to be probable event were excluded from the study cohort.
in three-one case each of pancytopaenia, leukopaenia and thrombocytopaenia. The time from first use was 5 weeks, 6 discontinued and all patients improved and were discharged The age distribution of the nine cases is similar to the distribution in the study population. Five patients (55%) from the hospital within 7 days.
Three patients had a newly-diagnosed blood disorder were male. where a causal relation was considered clinically only possible -two with a diagnosis of neutropenia and one with Discussion thrombocytopenia. All three patients recovered promptly after discontinuing the drug.
This population-based follow-up study was designed to Overall the estimated risk of probable or possible blood estimate the risk of hospitalization for blood and skin disorders among co-trimoxazole users was 6/107 689 or disorders among users of co-trimoxazole at GHC in 5.6/100 000 (95%CI 2.6-12.2) ( Table 2) . otherwise healthy patients. In the more than 100 000 users identified we found only a small number of blood or skin illnesses in hospitalized patients that were conSkin disorders sidered to be probably or possibly causally related to Three patients had a diagnosis of either erythema multiforme co-trimoxazole. or Stevens Johnson syndrome-none with toxic epidermal Newly-diagnosed blood disorders occurred in six patients. necrolysis. A causal connection between the skin disorder There were two cases of neutropenia, two cases of and co-trimoxazole was considered to be probable in two thrombocytopenia, one case of leukopenia and one case of cases, both with a diagnosis of Stevens Johnson syndrome.
pancytopenia. Of these, three patients had an illness where In both patients co-trimoxazole was discontinued with co-trimoxazole was clinically implicated as the cause of the prompt recovery. A causal connection with co-trimoxazole illness. In the remaining three patients a causal connection seemed possible in one patient diagnosed with erythema to co-trimoxazole was considered clinically to be possible, multiforme. The duration of hospitalization in this case was but an alternate etiology could not be ruled out. Assuming only one day with subsequent recovery.
that all cases were caused by the study drug, the incidence The estimated risk of probable or possible skin disorders of co-trimoxazole-associated blood disorders was estimated among co-trimoxazole users was 3/107 689 or 2.8/100 000 to be 5.6/100 000 (95%CI 2.6-12.2). In all patients (95%CI 0.9-8.2).
co-trimoxazole was discontinued and all had a complete recovery. In a previously published cohort study using data Table 2 Risk of blood and skin disorders associated with from the GPRD in the UK we estimated the risk of co-trimoxazole.
hospitalization for important blood illnesses among those exposed to co-trimoxazole to be 0.9/100 000 (5). The study four of the six cases were hospitalized for less than 3 days (see Table 1 ). In our prior study such patients may well References have been treated as outpatients.
We found three cases of skin disorders that were of co-trimoxazole to be 2.6/100 000 [4] and with our prior
